Icon

MINOCYCLINE HYDROCHLORIDE (nda050451)- (EQ 100MG BASE,EQ 50MG BASE)

MINOCYCLINE HYDROCHLORIDE TRIAX PHARMS
EQ 100MG BASE,EQ 50MG BASE
No No
Expired Expired
None None
None No
MINOCYCLINE HYDROCHLORIDE Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species.
6 0 5
Total Other Developers 2
Drugs with Suitability Yes
EQ 100MG BASE ** ** - - 4
EQ 50MG BASE ** ** - - 3
NDA Sales Available Total Generic Sales Available
No 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ****** ******* ******, *** *********** * *** ***** **, ******** *****, *** **** (**) *****-****, ****** ****** (***) ***
****** ******* ******* *************** ******* *********** **** **. */*** ** ***, ***** *** ****-**, ****** *****, ****. *******, *******, ******* ******, ***** (***) ***
****** ** ****** **** *** *** ******* ******* *********** *-**, **, ***, **, **, **, **, ** & *-**, ****, ******* ****** ***** *****, ******, *****, ***** & *** ******, ***** (***) ***
****** *** ***** ********** ****** ************ (*****) ***.***. *********** ****. **. **. **********, ******* ********** ****, ********, *********** ******, ***** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-*, **. **. ***/*, ***/*, ***/*, **** **. *-*/*, ***** ***, ***** ********** ****, ********* (*******), ********* (******), ************ (********), ************, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.